Evidence map›Paper›PMID 41526088›Full record

SynthesisBMJ open quality2026

Role of real-world evidence from patient registries for psoriasis in decision-making: a systematic review.

Lauren Passero, Teresa A Simon, Yichen Zhong, Joe Zhuo, Stefan Varga, April W Armstrong

Abstract readSystematic Review
In one paragraph

Synthesis in BMJ open quality, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Lauren PasseroUniversity of North Carolina, Chapel Hill, North Carolina, USA.
Teresa A SimonWorldWide Health Economics & Outcomes Research, Bristol Myers Squibb, Princeton, New Jersey, USA.
Yichen ZhongWorldWide Health Economics & Outcomes Research, Bristol Myers Squibb, Princeton, New Jersey, USA.
Joe ZhuoWorldWide Health Economics & Outcomes Research, Bristol Myers Squibb, Princeton, New Jersey, USA.
Stefan VargaWorldWide Medical Immunology, Bristol Myers Squibb, Princeton, New Jersey, USA Stefan.Varga@bms.com.ORCID 0000-0003-1626-1507
April W ArmstrongDivision of Dermatology, David Geffen School of Medicine, University of California, Los Angeles, California, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionTreatment of moderate to severe psoriasis typically requires the use of multiple systemic therapies over a patient's lifetime. The efficacy and safety of systemic treatments are typically evaluated in clinical trials; however, patient registries are increasingly used to monitor long-term outcomes of systemic therapies for psoriasis in real-world settings. Psoriasis registries also generate important real-world evidence about psoriasis treatment that may facilitate a greater understanding of outcomes outside of a controlled clinical trial setting. This study thus characterises the design and measures used in real-world studies of psoriasis treatment from patient registries and assesses its use in informing clinical guidelines and reimbursement decisions. METHODS AND ANALYSIS: A systematic literature review was conducted to identify real-world observational studies that used psoriasis registry data. PubMed and Embase were searched for English-language studies published between January 2018 and January 2023. To assess how real-world studies, clinical guidelines, and reimbursement and coverage reports have informed practice, treatment, and reimbursement guidelines, a narrative review of recommendations was conducted. All results were screened by two independent reviewers (LP and TAS) using prespecified inclusion and exclusion criteria. Outcomes of interest were extracted into Excel, with all conflicts resolved through discussion/consensus. Tables displayed outcomes and research topics first by year, then by registry. PROSPERO REGISTRATION NUMBER: CRD42023402431.

Indexed as

Decision MakingPsoriasisRegistriesHumansClinical practice guidelinesDecision makingHealth policyOutcome Assessment, Health Care

Identifiers

PMID41526088
PMCPMC12815139

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.